loading...| Preferred Name |
yttrium Y 90 ibritumomab tiuxetan |
|
| Synonyms |
IDEC-Y2B8 monoclonal antibody |
|
| Definitions |
A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90). Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1812" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1812" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000038483 |
|
| altLabel |
IDEC-Y2B8 monoclonal antibody 90Y ibritumomab tiuxetan Y90 Zevalin IDEC Y2B8 |
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000038239 http://purl.bioontology.org/ontology/PDQ/CDR0000357562 |
|
| cui |
C1135144 C1134535 C0879283 |
|
| Date last modified |
2017-10-11 |
|
| definition |
A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90). Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1812" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1812" NCI Thesaurus) |
|
| Legacy PDQ ID |
11103 |
|
| NCI ID |
C1812 |
|
| notation |
CDR0000038483 |
|
| NSC Code |
710085 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
yttrium Y 90 ibritumomab tiuxetan |
|
| tui |
T109 T116 T129 T130 T121 |